HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggested that osimertinib could be effective in HER2 amplified or mutated lung cancer as a single agent or in combination.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2F7tolh
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου